Literature DB >> 25245964

Locoregional therapies in melanoma.

Andrea M Abbott1, Jonathan S Zager2.   

Abstract

In-transit disease is defined as any dermal or subcutaneous metastases that arise between the primary melanoma but not beyond the draining regional nodal basin. Patients who develop in-transit disease are at further risk to develop additional locoregional and distant disease. Treatment must be individualized and take into consideration the extent of disease, tumor characteristics, and patient characteristics including age, comorbidities, previous therapies, and site of recurrence. Surgery, regional perfusions and intralesional injections all play a role in management options. These patients should be discussed and managed by a multidisciplinary team whenever possible.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hyperthermic isolated limb perfusion; Intra-tumoral injections; Isolated limb infusion; Locoregional recurrence; Melanoma

Mesh:

Substances:

Year:  2014        PMID: 25245964     DOI: 10.1016/j.suc.2014.07.004

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  12 in total

1.  Advancements in unresectable melanoma: a multidisciplinary perspective.

Authors:  Mary-Kate Malecek; June K Robinson; Karl Bilimoria; Jennifer N Choi; Jaehyuk Choi; Pedram Gerami; Timothy Kruser; Timothy Kuzel; Mary Martini; Jonathan B Strauss; Jeffrey Wayne; Jeffrey Sosman; Sunandana Chandra
Journal:  Melanoma Manag       Date:  2016-08-16

Review 2.  A surgical perspective report on melanoma management.

Authors:  Brian D Wernick; Neha Goel; Francis Sw Zih; Jeffrey M Farma
Journal:  Melanoma Manag       Date:  2017-05-15

Review 3.  The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy.

Authors:  Siavash Raigani; Sonia Cohen; Genevieve M Boland
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

4.  Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.

Authors:  Minhyung Kim; Nickolay Neznanov; Chandler D Wilfong; Daria I Fleyshman; Andrei A Purmal; Gary Haderski; Patricia Stanhope-Baker; Catherine A Burkhart; Katerina V Gurova; Andrei V Gudkov; Joseph J Skitzki
Journal:  Cancer Res       Date:  2016-09-28       Impact factor: 12.701

5.  ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.

Authors:  Na Tosha N Gatson; Shiao-Pei S Weathers; John F de Groot
Journal:  CNS Oncol       Date:  2015-12-15

Review 6.  Developments in Intralesional Therapy for Metastatic Melanoma.

Authors:  Sarah Sloot; Omar M Rashid; Arnod A Sarnaik; Jonathan S Zager
Journal:  Cancer Control       Date:  2016-01       Impact factor: 3.302

Review 7.  Intralesional treatment of metastatic melanoma: a review of therapeutic options.

Authors:  Benjamin Weide; Dario Neri; Giuliano Elia
Journal:  Cancer Immunol Immunother       Date:  2017-01-11       Impact factor: 6.968

Review 8.  The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.

Authors:  Emmanuel Gabriel; Joseph Skitzki
Journal:  Cancers (Basel)       Date:  2015-07-01       Impact factor: 6.639

9.  Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study.

Authors:  Tavis A Read; Aaron Smith; Janine Thomas; Michael David; Matthew Foote; Michael Wagels; Andrew Barbour; B Mark Smithers
Journal:  J Surg Oncol       Date:  2018-03-12       Impact factor: 3.454

10.  Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.

Authors:  Hansje-Eva Teulings; Esther P M Tjin; Karina J Willemsen; Stephanie van der Kleij; Sylvia Ter Meulen; E Helen Kemp; Gabrielle Krebbers; Carel J M van Noesel; Cornelis L M C Franken; Jan W Drijfhout; Cornelis J M Melief; Ludmila Nieuweboer-Krobotova; Omgo E Nieweg; Jos A van der Hage; J P Wietze van der Veen; Germaine N Relyveld; Rosalie M Luiten
Journal:  Oncoimmunology       Date:  2018-01-15       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.